... Jun 23
It is important to note that tofacitinib has not been approved or authorized for use by any regulatory authority worldwide for the treatment of COVID-... Jun 17
These doses are part of Pfizer and BioNTech’s previously announced pledge to provide two billion doses of the COVID-19 vaccine to low- and ... Jun 10
While the pseudovirus system used is a surrogate for authentic SARS-CoV-2, previous studies have shown excellent concordance between pseudotype neutralization and SARS-CoV-... Jan 21
Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure the ... Jan 13
CIFFREO is a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study.... Jan 07
Pfizer inc. and OPKO Health Inc. announced today that the USFDA has accepted for filing the initial Biologics License Application for somatrogon, a long-acting ... Jan 05
... Dec 24
The FDA’s acceptance of our application for 20vPnC is yet another significant milestone in Pfizer’s continuing efforts to help protect adults against pneumococcal ... Dec 09
... Dec 08
We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of ... Dec 07
... Dec 02
An anti-tissue factor pathway inhibitor being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.... Nov 23
... Nov 19
... Nov 09
... Oct 27
We are proud of the transformative impact IBRANCE has had on the treatment of HR+, HER2- metastatic breast cancer... Oct 09
Clinical Study proves weekly administration of Somatrogon more effective in treating human growth deficiency disease... Oct 09
The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to ... Oct 07
Pfizer Inc. today announced the initiation of a rolling submission to the EMA for SARS-Cov-2 vaccine... Oct 06
Pfizer Inc. today announced that its investigational gene therapy candidate being developed to treat Duchenne muscular dystrophy ... Oct 01
Pfizer Inc. announced XELJANZ (tofacitinib) for the treatment of children 2 years and older with active polyarticular course juvenile idiopathic arthritis... Sep 28
Pfizer Inc. today announced that the U.S. FDA has accepted and granted priority review to the Company’s supplemental New Drug Application for XALKORI ... Sep 23
Pfizer and BioNTech choose lead mRNA vaccine candidate against COVID-19 and Pivotal Phase Global Study ... Aug 01
-Advertisements-
Wednesday, May 15, 2024
.jpeg)
